Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women (PAMG-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03715530|
Recruitment Status : Terminated (Data collection has halted due to no further assays provided by AmniSURE)
First Posted : October 23, 2018
Results First Posted : October 3, 2019
Last Update Posted : October 3, 2019
AmniSure International LLC
Information provided by (Responsible Party):
Mark Santillan, University of Iowa
|Study Design||Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Diagnostic|
Device: PAMG-1 immunoassay
Data collection has halted due to no further assays provided by AmniSURE.
No statistical analysis was completed at this time.